We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Quarterly intravenous ibandronate for postmenopausal osteoporosis.
- Authors
Emkey, Ronald D.
- Abstract
Osteoporosis is under-recognized and undertreated among postmenopausal women. Nitrogen-containing bisphosphonates are its first-line pharmacotherapy. Oral bisphosphonate treatment requires stringent dosing guidelines to minimize gastrointestinal irritation and enhance absorption. This paper reviews the efficacy, safety and tolerability of quarterly intravenous ibandronate 3 mg injection, approved in 2006 in the USA and Europe. Quarterly intravenous ibandronate injection has shown superior efficacy to daily oral ibandronate for bone mineral density increase and fracture prevention. No drug-related serious atrial fibrillation events have been reported with intravenous ibandronate. The regimen has a favorable renal safety profile. Quarterly intravenous ibandronate is administered as a simple 15-s intravenous injection in a physician's office and provides a beneficial option for patients who are unable to tolerate oral administration.
- Subjects
OSTEOPOROSIS in women; OSTEOPOROSIS prevention; DIPHOSPHONATES; ABSORPTION (Physiology); DIGESTIVE organ blood vessel radiography; DRUG administration
- Publication
Women's Health (17455057), 2008, Vol 4, Issue 3, p219
- ISSN
1745-5057
- Publication type
Article
- DOI
10.2217/17455057.4.3.219